STAAR Surgical Company
STAA · NASDAQ
11/5/2025 | 9/26/2025 | 6/27/2025 | 3/28/2025 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 113.7% | 4.1% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $0 | $0 | $0 |
| % Margin | – | 82.2% | 74% | 65.8% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $0 | $0 | $0 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $0 | $0 | $0 |
| Operating Income | – | $0 | -$0 | -$0 |
| % Margin | – | 19.5% | -67.6% | -134.8% |
| Other Income/Exp. Net | – | $0 | $0 | $0 |
| Pre-Tax Income | – | $0 | -$0 | -$0 |
| Tax Expense | – | $0 | -$0 | -$0 |
| Net Income | – | $0 | -$0 | -$0 |
| % Margin | – | 9.4% | -37.9% | -127.3% |
| EPS | – | 0.18 | -0.34 | -1.1 |
| % Growth | – | 152.9% | 69.1% | – |
| EPS Diluted | – | 0.18 | -0.34 | -1.1 |
| Weighted Avg Shares Out | – | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | – | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $0 | $0 |
| EBITDA | – | $0 | -$0 | -$0 |
| % Margin | – | 27.9% | -51.3% | -76.1% |